North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Size (2024 - 2029)

The North America SGLT2 market is projected to experience significant growth over the forecast period, driven by the increasing demand for SGLT2 inhibitors, which are used to manage blood sugar levels in individuals with type 2 diabetes. The market's expansion is influenced by the heightened focus on diabetes management, particularly in the context of COVID-19, which has exacerbated diabetes risks. The FDA-approved SGLT2 inhibitors, including various formulations, play a crucial role in this market, although their use is not authorized for type 1 diabetes due to safety and efficacy concerns.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hyperglycemics Research North America Sodium-Glucose Cotransporter Industry Market Size

Market Size of North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Industry

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 7.39 Billion
Market Size (2029) USD 10.99 Billion
CAGR (2024 - 2029) 8.67 %
Market Concentration High

Major Players

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Major Players

*Disclaimer: Major Players sorted in no particular order

North America SGLT2 Market Analysis

The North America Sodium-Dependent Glucose Co-Transporter 2 Market size is estimated at USD 7.39 billion in 2024, and is expected to reach USD 10.99 billion by 2029, growing at a CAGR of 8.67% during the forecast period (2024-2029).

COVID-19 significantly exacerbate Diabetes risks because the virus binds to pancreatic cells that produce insulin and could exert a toxic effect on them. In fact, they point out, studies of the earlier SARS-CoV-1 virus found that many infected patients had increased blood sugar. Drugmakers are rushing to advance potential treatments for the fast-spreading virus outbreak that has infected more people globally and so far, many were killed by the respiratory illness, according to a Reuters tally. SGLT2 inhibitors drug maker, AstraZeneca said 'it is committed to finding new solutions to fight COVID-19 by investigating the application of new and existing medicines.'

An FDA-approved group of prescription drugs known as SGLT2 inhibitors is used in combination with diet and exercise to decrease blood sugar levels in persons with type 2 diabetes. SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin as medications. They can be found as one-ingredient formulations or in mixtures with other diabetic medications like metformin. By encouraging the kidneys to eliminate sugar from the body through the urine, SGLT2 inhibitors reduce blood sugar levels. The FDA has not authorized SGLT2 inhibitors for use in individuals with type 1 diabetes because their safety and effectiveness in these patients have not been shown.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America SGLT2 Industry Segmentation

A class of antihyperglycemic medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors works by inhibiting the SGLT-2 proteins found in the renal proximal convoluted tubules. It works by preventing filtered glucose from being reabsorbed into the tubular lumen. North America's sodium-dependent glucose cotransporter 2 market witnessed USD 7.1 billion in the current year and is anticipated to register a CAGR of over 10% during the forecast period. The North American Sodium-dependent Glucose Cotransporter 2 Market is segmented by drugs (Invokana, Jardiance, and Farxiga/Forxiga) and geography (United States, Canada, and rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.

Drug
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Invokana (Canagliflozin)
Geography
United States
Canada
Rest of North America
Need A Different Region Or Segment?
Customize Now

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Size Summary

The North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) market is poised for significant growth, driven by the increasing prevalence of type 2 diabetes and the rising obesity rates in the region. SGLT2 inhibitors, such as canagliflozin, dapagliflozin, and empagliflozin, are FDA-approved medications that help lower blood sugar levels by promoting the excretion of glucose through urine. These drugs are used in conjunction with diet and exercise and are particularly beneficial for patients with type 2 diabetes and cardiovascular conditions. The market is characterized by a consolidated landscape, with major pharmaceutical companies like Janssen Pharmaceutical, Eli Lilly, AstraZeneca Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals holding substantial market shares. The United States, in particular, is expected to dominate the market due to its premium pricing strategy and favorable insurance policies that reimburse a significant portion of drug costs.

The COVID-19 pandemic has further underscored the importance of SGLT2 inhibitors, as the virus has been shown to exacerbate diabetes risks by affecting insulin-producing pancreatic cells. This has prompted drug manufacturers to expedite the development of treatments, including the exploration of existing medications like SGLT2 inhibitors for COVID-19-related complications. The market's growth is also supported by the FDA's approval of new indications for these drugs, such as their use in heart failure treatment, which expands their therapeutic applications. The increasing focus on managing diabetes and its associated cardiovascular risks, coupled with the strategic advancements by key players in the pharmaceutical industry, is expected to drive the market's expansion in North America over the forecast period.

Explore More

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Jardiance (Empagliflozin)

      2. 2.1.2 Farxiga/Forxiga (Dapagliflozin)

      3. 2.1.3 Invokana (Canagliflozin)

    2. 2.2 Geography

      1. 2.2.1 United States

      2. 2.2.2 Canada

      3. 2.2.3 Rest of North America

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Size FAQs

The North America Sodium-Dependent Glucose Co-Transporter 2 Market size is expected to reach USD 7.39 billion in 2024 and grow at a CAGR of 8.67% to reach USD 10.99 billion by 2029.

In 2024, the North America Sodium-Dependent Glucose Co-Transporter 2 Market size is expected to reach USD 7.39 billion.

North America SGLT2 Market Report Snapshots

North America SGLT2 Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)